MoonLake Immunotherapeutics - Class A —— 资产负债表 (NASDAQ:MLTX) | MetaTrader

展开完整图表

Financials

概览声明统计

每季度年度

总资产 116.63 M115.84 M76.84 M526.54 M477.93 M424.43 M 负债总额 4.15 M7.9 M8.08 M13.05 M24.54 M119.95 M 权益总额 5 M-7.06 M68.77 M513.49 M453.39 M304.48 M 负债及股东权益总额 116.63 M115.84 M76.84 M526.54 M477.93 M424.43 M 总债务 58.06 K0———75.71 M 净债务 -1.28 M-666.79 K———-318.26 M

新闻

Clear Street上调Moonlake目标价,看好IL-17数据

Clear Street raises Moonlake stock price target on IL-17 data

Cantor Fitzgerald重申Moonlake股票评级,看好强直性脊柱炎市场潜力

Cantor Fitzgerald reiterates Moonlake stock rating on axSpA potential

H.C. Wainwright基于试验结果将Moonlake Immunotherapeutics目标价上调至40美元

Moonlake Immunotherapeutics stock price target raised to $40 by H.C. Wainwright on trial results

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake股价因axSpA试验数据积极而飙升

MoonLake stock surges on positive axSpA trial data

InvestingPro公允价值预测后MoonLake股价飙升63%